Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
March 23 2023 - 8:30AM
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the
“Company”), a clinical-stage pharmaceutical company developing
innovative therapies for the treatment of advanced solid tumors and
other serious diseases, today announced that the Company will
report its financial results for the three and twelve months ended
December 31, 2022, on Thursday, March 30, 2023, after the close of
trading and will host a conference call at 4:30 p.m. Eastern time.
The Company is utilizing a new conference call service. Those
wishing to participate must register for the conference call by way
of the following link: CLICK HERE TO REGISTER. Registered
participants will receive an email containing conference call
details for dial-in options. To avoid delays, we encourage
participants to dial into the conference call fifteen minutes ahead
of the scheduled start time.
A live webcast of the call will also be accessible under the
Investors & News section of the Company’s website and will be
available for replay beginning two hours after the conclusion of
the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company
dedicated to the discovery, development, and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s lead investigational product
candidate, LSTA1 (formerly known as CEND-1), LSTA1 is an
investigational drug designed to activate a novel uptake pathway
that allows co-administered or tethered anti-cancer drugs to
penetrate solid tumors more effectively. LSTA1 actuates this active
transport system in a tumor-specific manner, resulting in
systemically co-administered anti-cancer drugs more efficiently
penetrating and accumulating in the tumor, while normal tissues are
not affected. LSTA1 also has the potential to modify the tumor
microenvironment (“TME”), with the objective of making tumors more
susceptible to immunotherapies LSTA1 has demonstrated favorable
safety, tolerability, and activity in clinical trials to enhance
delivery of standard-of-care chemotherapy for pancreatic cancer.
Lisata and its collaborators have also amassed significant
non-clinical data demonstrating enhanced delivery of a range of
emerging anti-cancer therapies, including immunotherapies and
RNA-based therapeutics. Lisata is exploring the potential of LSTA1
to enable a variety of treatment modalities to treat a range of
solid tumors more effectively. In addition, Lisata has clinical
development programs based on its autologous CD34+ cell therapy
technology platform. For more information on the Company, please
visit www.lisata.com.
Contact:
Investors and Media:
Lisata Therapeutics, Inc.John MendittoVice President, Investor
Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Sep 2023 to Sep 2024